Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories (IDXX) delivers essential diagnostic solutions and practice management tools for veterinary professionals worldwide. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments shaping animal healthcare innovation.
Access official press releases and verified news covering financial results, product launches, regulatory milestones, and strategic partnerships. Our curated collection ensures transparent tracking of IDXX's advancements in in-clinic testing systems, reference laboratory services, and integrated practice software solutions.
Key updates include earnings announcements, diagnostic technology innovations, livestock health initiatives, and global expansion efforts. Bookmark this page for efficient monitoring of developments affecting veterinary diagnostics markets and IDXX's position as a leader in animal health solutions.
IDEXX Laboratories (NASDAQ: IDXX), a leader in veterinary diagnostics, will participate in two upcoming conferences. On February 24 at 9:55 am EST, executives Tina Hunt and Brian McKeon will engage in a virtual fireside chat at the BofA Securities Animal Health Summit. Following that, on March 7 at 11:00 am EST, CEO Jay Mazelsky will present at the 43rd Annual Raymond James Institutional Investors Conference. Live webcasts and archived editions of the presentations will be accessible on the IDEXX website.
IDEXX Laboratories reported an 11% increase in fourth quarter revenue, totaling $801 million, primarily driven by a 13% growth in CAG Diagnostics recurring revenue. Full-year revenue reached $3,215 million, up 19%, with an EPS of $8.60, a 28% increase. The company anticipates 2022 revenue of $3.5-$3.565 billion and EPS of $9.27-$9.59. Despite strong overall performance, LPD segment revenue declined 20% due to prior year high testing demand. The company remains positive about growth in companion animal healthcare.
PetDx has announced a collaboration with IDEXX Laboratories to enhance access to its liquid biopsy test for canine cancer, OncoK9. This test, which allows for noninvasive cancer detection through a simple blood draw, will be available to veterinary customers in the U.S. and Canada by the end of January 2022. OncoK9 utilizes advanced genomic analysis and sequencing technology, showing promising results in clinical studies. With an estimated six million new canine cancer diagnoses annually, this collaboration aims to improve diagnostics and care for dogs suffering from cancer.
IDEXX Laboratories (NASDAQ: IDXX) announced enhancements to its products and services aimed at improving veterinary practices' efficiency amidst rising patient volumes. Key enhancements include clinical decision support for the IDEXX 4Dx® Plus Test, improvements to the VetConnect® PLUS Mobile App, advanced software for the SediVue Dx® Urine Sediment Analyzer, and a new Catalyst® SDMA Test to streamline workflows. These innovations are designed to aid veterinarians in making quicker, confident clinical decisions, reflecting IDEXX's commitment to supporting the growing demands of veterinary professionals.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the expansion of its reference laboratory tests to improve cancer diagnosis and treatment for veterinarians. This new offering includes a liquid biopsy test using DNA sequencing for common canine cancers, a diagnostic panel for identifying genetic mutations, and innovative diagnostic profiles for therapy management. With around 6 million new cancer diagnoses annually in dogs and cats in the U.S., IDEXX aims to support veterinarians in managing complex cancer cases more effectively.
IDEXX Laboratories (NASDAQ: IDXX) will announce its 2021 fourth quarter and full year financial results on February 2, 2022, before market opening. An analyst conference call will follow at 8:30 a.m. ET, accessible via a live webcast on the IDEXX website. This event will also be available by telephone, requiring an access code. IDEXX specializes in veterinary diagnostics and practice software, operating globally with around 9,800 employees. The company is a member of the S&P 500 Index, providing innovative solutions to veterinarians and ensuring quality in water and food safety.
IDEXX Laboratories reported a 12% revenue growth for Q3 2021, reaching $810 million. The Companion Animal Group (CAG) Diagnostics saw significant contributions with a 13% increase in recurring revenue. Earnings per share (EPS) stood at $2.03, marking a 20% growth. IDEXX updated its 2021 guidance, projecting revenue growth between 17.5% - 18% and EPS growth of 24% - 25%. CAG capital instrument revenues surged 34%. However, Livestock, Poultry, and Dairy (LPD) revenues declined 21% as compared to last year.
IDEXX Laboratories, a leader in veterinary diagnostics, will announce its third quarter financial results for 2021 on November 2, 2021, before markets open. The company will host an analyst conference call at 8:30 a.m. ET on the same day. Access to the live call will be available through IDEXX's website and via telephone. IDEXX employs around 9,800 people and provides diagnostics and software for veterinary, livestock, and water quality sectors, serving customers in over 175 countries.
IDEXX Laboratories (NASDAQ: IDXX) will host a virtual Investor Day on August 12, 2021, from 10:00 AM to 12:30 PM EDT. This event features presentations by senior leadership, including CEO Jay Mazelsky and CFO Brian McKeon, followed by a Q&A session. Participants can access the live webcast and slide presentations via IDEXX's investor page. An archived replay will be available shortly after the event. IDEXX is recognized for its innovative solutions in veterinary diagnostics, software, and water testing.
IDEXX Laboratories announced strong second quarter results for 2021, with a reported revenue growth of 30% and organic revenue growth of 25%. The Companion Animal Group (CAG) Diagnostics saw recurring revenue growth of 30% reported and 26% organic. The earnings per share (EPS) reached $2.34, a 36% increase. The company raised its 2021 revenue guidance to $3.170 - $3.205 billion and EPS outlook to $8.20 - $8.36. Growth drivers include strong demand for CAG Diagnostics and expansion in water testing revenues.
